Literature DB >> 10509013

A selection system for human apoptosis inhibitors using yeast.

W Greenhalf1, J Lee, B Chaudhuri.   

Abstract

Apoptosis is a regulated series of events which leads to the death and elimination of mammalian cells during development or in disease control. It is regulated in part by members of the Bcl-2 family of genes. Some of these stimulate cell death, while others prevent it. Expression of one of these death inducers, Bax-alpha (Bax), in the yeast Saccharomyces cerevisiae induces growth arrest and subsequently can cause cell death. Proteins of the Bcl-2 family that are known to inhibit apoptosis in mammalian cells overcome Bax-induced growth arrest in yeast. We describe here a system for isolation of human genes that are able to overcome Bax sensitivity in yeast. Two novel proteins, identified with this system, have been named 'Bax antagonists selected in saccharomyces' (BASS). These proteins not only overcome toxicity of Bax in yeast but also protect mammalian cells from apoptosis that is induced by staurosporine or Bax overexpression. We find that BASS2 is the more effective of the two genes. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10509013     DOI: 10.1002/(SICI)1097-0061(19990930)15:13<1307::AID-YEA455>3.0.CO;2-3

Source DB:  PubMed          Journal:  Yeast        ISSN: 0749-503X            Impact factor:   3.239


  8 in total

1.  SON protein regulates GATA-2 through transcriptional control of the microRNA 23a~27a~24-2 cluster.

Authors:  Erin Eun-Young Ahn; Tsunehito Higashi; Ming Yan; Shinobu Matsuura; Christopher J Hickey; Miao-Chia Lo; Wei-Jong Shia; Russell C DeKelver; Dong-Er Zhang
Journal:  J Biol Chem       Date:  2013-01-14       Impact factor: 5.157

Review 2.  The role of SON in splicing, development, and disease.

Authors:  Xinyi Lu; Huck-Hui Ng; Paula A Bubulya
Journal:  Wiley Interdiscip Rev RNA       Date:  2014-04-30       Impact factor: 9.957

3.  A streamlined process to phenotypically profile heterologous cDNAs in parallel using yeast cell-based assays.

Authors:  S Tugendreich; E Perkins; J Couto; P Barthmaier; D Sun; S Tang; S Tulac; A Nguyen; E Yeh; A Mays; E Wallace; T Lila; D Shivak; M Prichard; L Andrejka; R Kim; T Melese
Journal:  Genome Res       Date:  2001-11       Impact factor: 9.043

4.  An approach to genomewide screens of expressed small interfering RNAs in mammalian cells.

Authors:  Lianxing Zheng; Jun Liu; Sergei Batalov; Demin Zhou; Anthony Orth; Sheng Ding; Peter G Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-19       Impact factor: 11.205

5.  Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis.

Authors:  Eun-Young Ahn; Ming Yan; Oxana A Malakhova; Miao-Chia Lo; Anita Boyapati; Hans Beier Ommen; Robert Hines; Peter Hokland; Dong-Er Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-24       Impact factor: 11.205

6.  Identification of the essential Brucella melitensis porin Omp2b as a suppressor of Bax-induced cell death in yeast in a genome-wide screening.

Authors:  Géraldine Laloux; Michaël Deghelt; Marie de Barsy; Jean-Jacques Letesson; Xavier De Bolle
Journal:  PLoS One       Date:  2010-10-11       Impact factor: 3.240

7.  A functional yeast survival screen of tumor-derived cDNA libraries designed to identify anti-apoptotic mammalian oncogenes.

Authors:  Moritz Eißmann; Bettina Schwamb; Inga Maria Melzer; Julia Moser; Dagmar Siele; Ulrike Köhl; Ralf Joachim Rieker; David Lukas Wachter; Abbas Agaimy; Esther Herpel; Peter Baumgarten; Michel Mittelbronn; Stefanie Rakel; Donat Kögel; Stefanie Böhm; Tony Gutschner; Sven Diederichs; Martin Zörnig
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

8.  EGR1 decreases the malignancy of human non-small cell lung carcinoma by regulating KRT18 expression.

Authors:  Huihua Zhang; Xiaojia Chen; Jiakang Wang; Wenhua Guang; Wei Han; Hang Zhang; Xuan Tan; Yong Gu
Journal:  Sci Rep       Date:  2014-07-03       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.